You are here

Article Text

Article menu
Download PDFPDF
Case report
Ménétrier’s disease in a patient with refractory ulcerative colitis: a clinical challenge and review of the literature
  1. Sofia Rao1,2,
  2. Anna Viola1,
  3. Omar Ksissa1,2 and
  4. Walter Fries1
  1. 1IBD-unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
  2. 2Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Sicilia (omit), Italy
  1. Correspondence to Professor Walter Fries; fwalter{at}unime.it

Abstract

Ménétrier’s disease (MD) is a rare disease of the stomach, characterised by hypertrophic gastric folds leading to protein loss. The association with ulcerative colitis (UC) is rare but has been reported in the literature. We report a case of a 29-year-old male affected by UC with an additional diagnosis of MD 3 years after UC diagnosis. UC was refractory to several treatment lines (thiopurines, infliximab, vedolizumab and ustekinumab), and the patient underwent colectomy. Octreotide was administered for MD normalising blood biochemistry, but it was not effective in inducing endoscopic remission of the stomach. Treatment options in patients with MD and UC are discussed.

  • gastroenterology
  • inflammatory bowel disease
  • drugs: gastrointestinal system

http://dx.doi.org/10.1136/bcr-2021-246137

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors AV was involved in planning and conducting of the study. SR was involved in manuscript drafting. OK was involved in revision of the manuscript. WF was involved in planning and conducting of the study, and revision of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.